Suppression of Intimal Hyperplasia by a 5-lipoxygenase Inhibitor, MK-886: Studies with a Photochemical Model of Endothelial Injury

Summary

Intimal thickening is a major complication following percutaneous transluminal coronary angioplasty, which leads to restenosis and requires reoperation. We have investigated the effect of a 5-lipoxygenase inhibitor, MK-886, a leukotriene B₄ (LTB₄) receptor antagonist, ONO-4057 or a LTC₄ and LTD₄ receptor antagonist, ONO-1078, on intimal thickening. Photochemical reaction between green light and systemically administered Rose Bengal produced intimal thickening in the rat femoral artery. Each drug was administered orally, once a day for 7 days, starting just after the endothelial injury. Both MK-886 administration, 10 mg/kg, and ONO-4057 administration, 100 mg/kg, suppressed intimal thickening level examined three weeks after endothelial injury, while similarly administered ONO-1078 did not. In cultured rat-derived smooth muscle cells, LTB₄, an active metabolite of 5-lipoxygenase whose biosynthesis in air pouch exudate was suppressed by MK-886, stimulated cell migration. Based on these observations, the 5-lipoxygenase may have a key role in intimal thickening via its metabolites such as LTB₄.

• References

• 1 Powell JS, Clozel JP, Müller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
• 2 Kikuchi S, Umemura K, Kondo K, Nakashima M. Tranilast, an anti-allergic drug, suppresses intimal hyperplasia after photochemically-induced endothelial injury in the spontaneously hypertensive rat. Eur J Pharmacol 1996; 295: 221-7.
• 3 Fingerle J, Sander KH, Fotev Z. α₁-Receptor antagonists urapidil and prazosin inhibit neointima formation in rat carotid artery induced by balloon catheter injury. Basic Res Cardiol 1991; 86: 75-81.
• 4 Hirosumi J, Nomoto A, Ohkubo Y, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H. Inflammatory responses in cuff-induced atherosclerosis in rabbits. Atherosclerosis 1987; 64: 243-54.
• 5 Ross R. The pathogenesis of atherosclerosis - an update. New Engl J Med 1986; 314: 488-500.
• 6 Kienbaum P, Braun M, Hohlfeld Th, Weber AA, Sarbia M, Schroer K. Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function. J Cardiovasc Phamacol 1995; 25: 774-8.
• 7 Mohacsi A, Fulop Jr T, Kozlovszky B, Hauck M, Kiss I, Leovey A. Sera and leukocyte elastase-type protease and antiprotease activity in healthy and atherosclerotic subjects of various ages?. J Gerontol 1992; 47 (05) B154-8.
• 8 Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, Nakashima M. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants: studies with a photochemically induced thrombosis model in the guinea pig femoral artery. Eur J Pharmacol 1994; 264: 191-8.
• 9 Hirata Y, Umemura K, Kondoh K, Uematsu T, Nakashima M. Experimental intimal thickening studies using the photochemically induced thrombosis model in the guinea-pig femoral artery. Atherosclerosis 1994; 107: 117-24.
• 10 Saniabadi A. Photosensitisers and photochemical reactions. In: A novel photochemical model for thrombosis research and evaluation of antithrombotic and thrombolytic agents. Nakashima M. ed. Churchill Livingstone; London, New York, Tokyo: 1994. pp. 1-19.
• 11 Saniabadi AR, Umemura K, Matsumoto N, Sakuma S, Nakashima M. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost 1995; 73 (05) 868-72.
• 12 Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71 (04) 1207-10.
• 13 Nakao J, Ooyama T, Chang WC, Murota S, Orimo H. Platelets stimulate aortic smooth muscle cell migration in vitro. Atherosclerosis 1982; 43: 143-50.
• 14 Konno S, Tsurufuji S. Induction of Zymosan-air-pouch inflammation in rats and its characterization with reference to the effects of anticomplementary and anti-inflammatory agents. Br J Pharmacol 1983; 80: 269-77.
• 15 Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, Piechuta H, Riendeau D, Rouzer CA, Rokach J, Young R, MacIntyre DE, Peterson L, Bach T, Eier-mann G, Hopple S, Humes J, Hupe L, Luell S, Metzger J, Meurer R, Miller DK, Opas E, and Pacholok S. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1989; 67: 456-64.
• 16 Rouzer CA, Ford-Hutchinson W, Morton HE, Gillard JW. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 1990; 265 (03) 1436-42.
• 17 Kishikawa K, Tateishi N, Maruyama T, Seo R, Toda M, Miyamoto T. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins 1992; Oct 44 (04) 261-75.
• 18 Iwamoto I, Tomoe S, Tomioka H, Yoshida S. Leukotriene B4 mediates substance P-induced granulocyte infiltration into mouse skin. Comparison with antigen-induced granulocyte infiltration. J Immunology 1993; 151 (04) 2116-23.
• 19 Obata T, Okada Y, Motoishi M, Nakagawa N, Terawaki T, Aishita H. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol 1992; Nov 60 (03) 227-37.
• 20 Metters KM, Gareau Y, Lord A, Rochette C, Sawyer N. Characterization of specific binding sites for cysteinyl leukotrienes in sheep lung. J Pharmacol Exp Ther 1994; Jul 270 (01) 399-406.
• 21 Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986; 46: 155-69.
• 22 Fuster V, Bandimon JJ, Bandimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992; 86 III III-1-III-11.
• 23 Rainces EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989; 243: 393-6.
• 24 Wang X, Feuerstein GZ, Clark RK, Yue TL. Enhanced leucocyte adhesion to interleukin-1 beta stimulated vascular smooth muscle cells is mainly through intercellular adhesion molecule-1. Cardiovasc Res 1994; 28: 1808-14.
• 25 Fantone JC, Kinnes DA. Prostaglandin E₁ and prostaglandin I₂ modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 1983; 113: 506-12.
• 26 Sedgwick JB, Berube ML, Zurier RB. Stimulus-dependent inhibition of superoxide generation by prostaglandins. Clin Immunol Immunopathol 1985; 34: 205-15.
• 27 Totani L, Piccoli A, Pellegrini G, Di Santo A, Lorenzet R. Polymorpho-nuclear leukocytes enhance release of growth factors by cultured endothelial cells. Arteriosclerosis & Thrombosis 1994; Jan 14 (01) 125-32.
• 28 Porreca E, Di Febbo C, Di Sciullo A, Angelucci D, Nasuti M, Vitullo P, Reale M, Conti P, Cuccurullo Poggi A. Cysteinyl leukotriene D₄ induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 1996; 76 (01) 99-104.
• 29 Palmberg L, Claesson HE, Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle cells. J Cell Sci 1987; 88: 151-9.